IDEXX Laboratories (IDXX) carries a deeply negative liquidation value under the standard haircut framework. Total assets of $3.39B are heavily concentrated in non-recoverable categories: goodwill ($412M, zero recovery), other intangibles ($105M, zero recovery), operating lease ROU assets ($121M, zero recovery under liquidation), capitalized contract costs and deferred costs ($187M noncurrent, zero recovery), and contract assets ($241M noncurrent, near-zero in wind-down). Tangible hard assets that attract any meaningful haircut are limited: cash ($201M at 100%), net receivables ($604M gross, $590M net of $14M allowance, at 90-95% recovery roughly $545-560M), and inventory ($382M at 60% recovery roughly $229M). Net PP&E of $740M at 50-70% recovery yields $370-518M. Applying conservative midpoints, gross recoverable asset value falls in the $1.5-1.7B range against total liabilities of $1.83B at face value. Equity book value of $1.56B is fictively supported by $6.93B in treasury stock buybacks (accumulated contra-equity) against $6.67B in retained earnings. Under liquidation, equity recovery is negative by approximately $130-330M before considering accelerated wind-down costs, lease termination penalties, and the $530M credit facility drawn balance. The credit facility balance increased materially from $398M at December 31, 2025 to $530M at March 31, 2026, a $132M increase in one quarter, which shifts the liability stack unfavorably. Two tranches of senior notes face near-term maturity: $75M in September 2026 and $75M in February 2027, representing execution risk in the liability stack. The filing discloses a $5M equity investment impairment in Q1 2026, though the XBRL tag AssetImpairmentCharges is tagged at $5M. No goodwill impairment. Operating lease total undiscounted payments are $145M with a present value liability of $126M; these do not extinguish on wind-down. Inventory turns of 1.4x indicate relatively slow-moving stock, consistent with specialized diagnostic consumables that have limited secondary market. The business model is dominated by intangible franchise value (installed base, reference lab network, software subscriptions) that yields zero in liquidation. MFFAIS CLV of negative $1.50B and OLV of negative $512M are consistent with this analysis. Compared to the prior filing (10-K, December 31, 2025), the primary balance-sheet changes are: credit facility drawn up $132M, working capital down from $265M to $154M, and cash up modestly from $180M to $201M.
▼ Community Notes